Keywords: |
cancer survival; acute granulocytic leukemia; leukemia, myeloid, acute; review; salvage therapy; cancer combination chemotherapy; cytarabine; methotrexate; drug megadose; cancer diagnosis; multiple cycle treatment; myeloperoxidase; maintenance therapy; cytogenetics; nccn clinical practice guidelines; practice guideline; hematopoietic stem cell transplantation; acute lymphoblastic leukemia; arsenic trioxide; cancer regression; acute leukemia; lumbar puncture; mitoxantrone; daunorubicin; promyelocytic leukemia; thrombocyte count; immunophenotyping; 5 aza 2' deoxycytidine; drug monitoring; blood cell count; idarubicin; flt3 ligand; hla typing; cytochemistry; retinoic acid; meningeal metastasis; partial thromboplastin time; mercaptopurine; central venous pressure; granulocytic sarcoma; oncogene c kit; nccn guidelines; randomized controlled trial (topic); acute myeloid leukemia; chemotherapeutic agents; leukemia treatment in older patients; prothrombin
|